An interventional study of Levofloxacin and Moxifloxacin in Cataract and Postoperative Endophthalmitis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Assiut University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Cataract by Assiut University — 3 open to participants now, 3 under way, none of them phase 3. Cataract · Assiut University.
Among the 13 studies in Cataract by Assiut University, this one is one of 3 that started in 2026, is one of 5 with no phase, and was the 13th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →3 of the 13 studies in Cataract by Assiut University are open now. Recruiting first, the newest first:
Assiut University
Ages 40+
Assiut University
Ages 40+
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 93 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 65 across the 7 interventional studies, 100 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Cataract by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07850414Assiut UniversityIntracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery | 2027-09-26 |
| NCT07821827Assiut UniversityCombined Phacoemulsification-Goniotomy in Primary Open-Angle and Primary Angle-Closure Glaucoma | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Cataract by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized study aims to compare the safety and efficacy of intracameral levofloxacin versus intracameral moxifloxacin administered at the end of phacoemulsification cataract surgery.
Postoperative endophthalmitis is a serious complication of cataract surgery. Intracameral antibiotics are used to reduce this risk.
This study will randomly assign patients undergoing elective phacoemulsification to receive either intracameral levofloxacin, intracameral moxifloxacin, or no intracameral antibiotic (control). Patients will be followed for visual outcomes, anterior chamber inflammation, and corneal endothelial safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive 0.1 mL of preservative-free levofloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.
Drug: Levofloxacin
Patients will receive 0.1 mL of preservative-free moxifloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.
Drug: Moxifloxacin
Patients will undergo standard phacoemulsification without any intracameral antibiotic injection.
0.1 mL of preservative-free levofloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.
0.1 mL of preservative-free moxifloxacin 0.5% injected into the anterior chamber at the end of phacoemulsification.
Incidence of postoperative endophthalmitis
Proportion of eyes that develop culture-proven or clinically diagnosed postoperative endophthalmitis.
Time frame: 1 month
Mean best-corrected visual acuity
Mean best-corrected visual acuity (BCVA) in logMAR
Time frame: 1 month
Mean endothelial cell density
Mean corneal endothelial cell density (cells/mm²) measured by specular microscopy.
Time frame: 1 month
Mean anterior chamber cell grade
Mean grade of anterior chamber cells according to Standardization of Uveitis Nomenclature (SUN) criteria.
Time frame: 1 week
Incidence of postoperative corneal edema
Proportion of eyes with clinically significant postoperative corneal edema.
Time frame: 1 week
Mean central corneal thickness
Mean central corneal thickness in micrometers.
Time frame: 1 month
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 303 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 12 months is below that.
Counting every sponsor, half of 493 studies reached it within 17 months; a quarter within 9 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levofloxacin